Mark Bachleda's most recent trade in Galera Therapeutics Inc was a trade of 11,000 Common Stock done at an average price of $2.2 . Disclosure was reported to the exchange on March 16, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Galera Therapeutics Inc | Mark Bachleda | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.25 per share. | 16 Mar 2023 | 11,000 | 11,000 (0%) | 0% | 2.2 | 24,717 | Common Stock |
Galera Therapeutics Inc | Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 Feb 2023 | 135,000 | 135,000 | - | - | Stock Option (Right to Buy) | |
Galera Therapeutics Inc | Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Feb 2022 | 75,000 | 75,000 | - | - | Stock Option (Right to Buy) | |
Galera Therapeutics Inc | Mark Bachleda | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Oct 2021 | 200,000 | 200,000 | - | - | Stock Option (Right to Buy) |